Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
批准号:
7231208
负责人:
Carl W White
金额:
$56.13万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2011-11-30
关键词:
ABCA3 geneAcuteAdultAdult Respiratory Distress SyndromeAffectAirAlbuminsAlveolarAmniotic FluidAnemiaAngiogenic FactorAnimalsAreaAutopsyBirthBlood CirculationBlood VesselsBlood capillariesBlood flowBlood gasBreathingBronchoalveolar LavageBronchopulmonary DysplasiaCarrier ProteinsCellsCessation of lifeChronicClosureDataDevelopmentDiseaseDoseDuctalDuctus ArteriosusEconomic InflationEdemaEndothelial CellsEndotheliumEnvironmentEpithelialEpithelial CellsEpitheliumEquilibriumErythropoietinFaceFetal LungFetusFrequenciesGene ExpressionGene FamilyGenesGrowth and Development functionHomeostasisHyperoxiaHypertensionHypoxiaHypoxia Inducible FactorInfantInflammationInflammatoryInjuryKnock-outKnowledgeLecithinLeft pulmonary arteryLipidsLungLung ComplianceMeasurementMeasuresMechanicsMessenger RNAModelingNeonatalNewborn InfantNewborn Respiratory Distress SyndromeOperative Surgical ProceduresOxygenOxygen measurement, partial pressure, arterialPatent Ductus ArteriosusPerinatalPerinatal Pulmonary HypertensionPharmaceutical PreparationsPhenotypePregnancyPremature BirthPremature InfantPrimatesProcessProcollagen-Proline DioxygenaseProductionProteinsPulmonary CirculationPulmonary Gas ExchangePulmonary HypertensionPulmonary artery structureRecombinant ProteinsRelative (related person)RelaxationReportingResearch PersonnelRespiratory distressRespiratory physiologyRoleRouteSignal TransductionStructure of parenchyma of lungSurfaceSystemTerm BirthTherapeuticTherapeutic UsesThird Pregnancy TrimesterTissuesTransgenic MiceVascular Endothelial Growth FactorsVascular remodelingVasodilationWeekangiogenesisascorbatebasecapillarycofactorcostcytokinefetalhemodynamicshuman NOS3 proteinhypoxia inducible factor 1improvedin uteroin vitro Modelin vivoindexinginhibitor/antagonistinstrumentinstrumentationlipid transportlung developmentlung hypoxiamorphometryneonatal pulmonary hypertensionneonatepersistent pulmonary hypertensionpostnatalprenatalpressureprogramsprotein expressionreceptorsurfactanttrendvascular bed
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Pulmonary hypertension (PHN) in respiratory distress syndrome (RDS) evolving to bronchopulmonary
dysplasia (BPD) results acutely from poor lung inflation and increased blood flow through the patent ductus
arteriosus, and chronically from altered reactivity, vascular remodeling, and hypoplasia of the pulmonary
vascular bed. The lung develops in relative hypoxia compared to 21% 02 seen at normal term delivery and,
especially, to hyperoxia that preterm neonates commonly face. Hypoxia-inducible factors (HIFs) could lower
pulmonary artery pressures by modulating surfactant, ductus arteriosus, and pulmonary vascular
development. Preliminary data show that HIFs can impact lung expansion at birth, expression of
surfactant proteins and lipids, patency of the ductus arteriosus, and angiogenic factors and
processes in developing lungs - all of which canmodify pulmonary hypertension. Further data show
that HIFs are highly expressed and stable in third trimester fetal primate lungs, while one of them, HIF-1a,
declines dramatically after preterm birth. Using cofactors 02, Fe2+, oxoglutarate, and ascorbate, HIF prolyl-
hydroxylases (PHDs) specifically regulate HIFstability. We reported that PHDinhibitors (PHDi)
profoundly alter stability of HIFs and downstream gene expression (VEGF and its receptors) in lung
endothelial and epithelial cells, and fetal lung explants, even in extreme hyperoxia. We hypothesize that
PHDi can decrease PHNby restoring the fetal VEGF/eNOS axis and improving perinatal surfactant
homeostasis. We propose to examine effects of PHDi delivered antenatally or postnatally, and by differing
routes, in ovine models of RDS and persistent PHN in preterm and term ovine models, respectively.
Chronically instrumented fetal/neonatal lambs will have pre- and/or postnatal hemodynamic, blood gas, and
respiratory physiology measurements. In lung tissue from these animals, we will measure HIFs, HIF-
dependent gene products, surfactant proteins and lipids, inflammatory cytokines and cells, and lung
morphometry to assess vascular development and remodeling. Results will provide valuable information
about pathophysiologic roles of HIFs in perinatal PHN and potential therapeutic uses of PHDi in RDS and
PHN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effect of vaping on COVID-19 infection
-
批准号:10176655
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2016
-
负责人:Carl W White
-
依托单位:
Development of antidotes for toxic gases
-
批准号:9145045
-
项目类别:
-
资助金额:$343.54万
-
财政年份:2016
-
负责人:Carl W White
-
依托单位:
Development of antidotes for toxic gases
-
批准号:9564911
-
项目类别:
-
资助金额:$323.1万
-
财政年份:2016
-
负责人:Carl W White
-
依托单位:
New Developments in Chemical Countermeasures: CounterACT 2018
-
批准号:9490163
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2016
-
负责人:Carl W White
-
依托单位:
Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
-
批准号:8214146
-
项目类别:
-
资助金额:$6.48万
-
财政年份:2011
-
负责人:Carl W White
-
依托单位:
Administration
-
批准号:8115244
-
项目类别:
-
资助金额:$8.46万
-
财政年份:2010
-
负责人:Carl W White
-
依托单位:
HYPOXIA-INDUCIBLE FACTORS IN BPD
-
批准号:7716092
-
项目类别:
-
资助金额:$2.26万
-
财政年份:2008
-
负责人:Carl W White
-
依托单位:
CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY
-
批准号:7716163
-
项目类别:
-
资助金额:$2.26万
-
财政年份:2008
-
负责人:Carl W White
-
依托单位:
HYPOXIA-INDUCIBLE FACTORS IN BPD
-
批准号:7562475
-
项目类别:
-
资助金额:$6.0万
-
财政年份:2007
-
负责人:Carl W White
-
依托单位:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
-
批准号:7294907
-
项目类别:
-
资助金额:$148.46万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
-
批准号:8737370
-
项目类别:
-
资助金额:$14.35万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
-
批准号:8535756
-
项目类别:
-
资助金额:$238.36万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
-
批准号:8716747
-
项目类别:
-
资助金额:$240.27万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
-
批准号:7692065
-
项目类别:
-
资助金额:$12.18万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
-
批准号:7225100
-
项目类别:
-
资助金额:$154.13万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Administration
-
批准号:7235522
-
项目类别:
-
资助金额:$12.99万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Education
-
批准号:7235523
-
项目类别:
-
资助金额:$2.76万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel therapeutics for vesicants and toxic inhaled chemicals (U54)
-
批准号:8144994
-
项目类别:
-
资助金额:$254.03万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
-
批准号:7637913
-
项目类别:
-
资助金额:$156.38万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
-
批准号:7450894
-
项目类别:
-
资助金额:$152.41万
-
财政年份:2006
-
负责人:Carl W White
-
依托单位:
海外基金